Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Capital Expenditures (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Capital Expenditures data on record, last reported at -$13000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures fell 111.3% year-over-year to -$13000.0; the TTM value through Sep 2025 reached $240000.0, up 101.34%, while the annual FY2024 figure was $267000.0, 40.27% down from the prior year.
  • Capital Expenditures reached -$13000.0 in Q3 2025 per SGMO's latest filing, up from -$133000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $22.6 million in Q4 2021 and bottomed at -$18.0 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $1.6 million, with a median of $460000.0 recorded in 2024.
  • The widest YoY moves for Capital Expenditures: up 468.89% in 2021, down 463.26% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $22.6 million in 2021, then plummeted by 127.21% to -$6.2 million in 2022, then tumbled by 192.9% to -$18.0 million in 2023, then skyrocketed by 100.84% to $152000.0 in 2024, then tumbled by 108.55% to -$13000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$13000.0 in Q3 2025, -$133000.0 in Q2 2025, and $234000.0 in Q1 2025.